The Latest Breaking News from uniQure

uniQure shows rising price performance, earning an upgrade to its IBD Relative Strength Rating.

UniQure stock doubled Tuesday after the company reached a testing agreement with the FDA for its Huntington's disease treatment.

UniQure N.V. (NASDAQ:QURE) announced safety and biomarker data from 10 patients enrolled in the low-dose cohort of the ongoing Phase 1/2 trial of AMT-130 gene therapy for Huntington's disease.  Six of the ten enrolled patients received AMT-130, and four received an imitation surgical procedure in this randomized, blinded clinical trial in the U.S.…

The much-awaited one-year data for the entire low-dose cohort for UniQure NV's (NASDAQ: QURE) AMT-130 gene therapy in Huntington's disease is expected at any time.

Within the last quarter, uniQure (NASDAQ:QURE) has observed the following analyst ratings:

  uniQure (NASDAQ:QURE) reported its Q1 earnings results on Monday, May 2, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Understanding Value Stocks A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labelled as a value stock.

  uniQure (NASDAQ:QURE) reported its Q4 earnings results on Friday, February 25, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Earnings uniQure reported an EPS of $0.17.